Completed PHASE2 INTERVENTIONAL 3-arm NCT00004448

Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Interventions Placebo omega-3 fatty acids prednisone

Updated 6 times since 2017 Last updated: Apr 30, 2025 Started: Nov 30, 1997 Primary completion: Aug 31, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00004448, this PHASE2 trial focuses on IgA Glomerulonephritis and remains completed. Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), it has been updated 6 times since 1997, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Jun 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Jun 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Southwest Pediatric Nephrology Study Group

Data source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States